Immunosenescence — the gradual decline of immune function with age — reshapes how older adults respond to vaccines. Immunosenescence decreases the production and diversity of naive T cells through thymic involution and alters B cell compartments, while chronic low-grade inflammation known as inflammaging skews immune signaling. Janko Nikolich-Žugich University of Arizona has characterized these age-related shifts in cellular composition and function, showing how reduced repertoire diversity and altered signaling weaken the initiation of robust vaccine-induced immunity.
Biological mechanisms
At the cellular level, fewer naive T cells and accumulation of relatively exhausted or senescent memory T cells limit the capacity to recognize new antigens, reducing the generation of high-quality helper T cell support for B cell responses. B cells in older adults show diminished class-switch recombination and somatic hypermutation, producing antibodies that are lower in affinity and less durable. Antigen-presenting cells such as dendritic cells can have impaired migration and cytokine production, delaying or blunting early innate signals that shape adaptive responses. Claudio Franceschi University of Bologna described how inflammaging not only contributes to baseline immune activation but also distorts vaccine-driven responses, sometimes promoting short-lived or dysregulated antibody production.
Clinical and societal implications
These mechanistic changes translate into clinically relevant outcomes: many vaccines elicit lower peak antibody titers and shorter-lived protection in older populations, increasing susceptibility to severe disease. Janet E. McElhaney McMaster University has emphasized that adjuvants and higher antigen doses can partially compensate by enhancing innate activation and expanding responding lymphocytes, which is why adjuvanted influenza vaccines and high-dose formulations are recommended for older adults in several national programs. Contextual factors matter: nutritional status, multimorbidity, medication use, and environmental exposures in different regions modulate immunosenescence and vaccine effectiveness, making responses heterogeneous across communities.
Consequences extend beyond individual risk to health systems and societies, with higher hospitalization rates and greater strain during outbreaks. Addressing this requires tailored vaccine design, optimized dosing or adjuvant strategies, and public health approaches that consider cultural and territorial differences in aging, access to care, and baseline immune health. Ongoing translational research aims to refine vaccines and adjunctive measures to restore more youthful immune responsiveness in older adults.